Clinical Trial

Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients

Name: Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients — clinical trial record (NCT07021261)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

Evaluate the IDFS rate, overall survival (OS) rate, and safety profile of UTD2 combined with capecitabine versus capecitabine monotherapy as adjuvant therapy for triple-negative early breast cancer patients who did not achieve pathological complete response (pCR) after neoadjuvant therapy.

Trial Details

NCT Number	NCT07021261
Lead Sponsor	Fudan University
Conditions	Breast Cancer, TNBC
Enrollment	440 participants
Start Date	2025-06-16
Primary Completion	2030-06-16 (estimated)
Study Completion	2032-06-16 (estimated)
Updated on ClinicalTrials.gov	2025-06-13